Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Apellis Pharmaceuticals (Nasdaq: APLS) announced its participation in two major investor conferences in June 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Apellis Pharmaceuticals (Nasdaq: APLS) announced its participation in two major investor conferences in June 2022. The Jefferies Healthcare Conference features a fireside chat on June 9, 2022, at 4:30 p.m. ET, while the Goldman Sachs 43rd Annual Global Healthcare Conference will take place on June 15, 2022, at 9:20 a.m. PT. Both events will be available via live webcast and can be accessed from the company's website. Following the events, webcasts will be replayable for 90 days.
Details
News Market Reaction – APLS
The recorded move for APLS in the trading session of this news was +2.90%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will participate in the following investor conferences in June:
- Jefferies Healthcare Conference: Fireside chat on Thursday, June 9, 2022 at 4:30 p.m. ET.
- Goldman Sachs 43rd Annual Global Healthcare Conference: Fireside chat on Wednesday, June 15, 2022 at 9:20 a.m. PT.
The conference events will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. Replays of the webcasts will be available for 90 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in complement, we ushered in the first new class of complement medicine in 15 years with the approval of the first and only targeted C3 therapy. We are advancing this science to continually develop transformative medicines for people living with rare, retinal, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.